Veru partners with Novo Nordisk for obesity drug combination study

Veru Inc. (NASDAQ: VERU) entered into a clinical supply agreement with Novo Nordisk A/S on June 2, 2026, for the company's Phase 2b PLATEAU clinical study.

The study will evaluate the combination of Veru's enobosarm, an oral selective androgen receptor modulator, with Novo Nordisk's Wegovy (semaglutide for injection) in older adults with obesity who are receiving Wegovy therapy for weight reduction.

Under the agreement, Veru will conduct and sponsor the Phase 2b PLATEAU study while Novo Nordisk will supply Wegovy at no charge. Veru will provide Novo Nordisk with insights into obesity and weight management trial design, methodology, and clinical conduct, including regular study updates, protocol changes, and safety updates.

Veru retains full global development and commercialization rights to enobosarm. The company has granted Novo Nordisk a right of first negotiation if Veru intends to develop, commercialize, or license enobosarm intellectual property in combination with any Novo Nordisk GLP-1 product for any indication.

The information is based on a company press release.

You May Also Be Interested In

• Morgan Stanley Private Credit Fund Caps Redemptions At 5%
• Silvercorp GC Mine mineral resources rise 59% in updated report
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal